- Home
- NEXR vs BIAF Comparison
NEXR vs BIAF Comparison
Compare NEXR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEXR | BIAF |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Israel | United States |
| Employees | 38 | 57 |
| Industry | Other Specialty Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | NEXR | BIAF |
|---|---|---|
| Price | $0.47 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 18.1M | 540.0K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.23 |
| 52 Week High | $1.28 | $13.50 |
Technical Indicators
Market Signals| Indicator | NEXR | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 26.72 |
| Support Level | N/A | $0.69 |
| Resistance Level | $1.28 | $0.87 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 3.33 | 21.39 |
Price Performance
Historical ComparisonAbout NEXR Nexera Technologies Ltd Ordinary Shares
Nexera Technologies Ltd focuses on homeland security technologies, artificial intelligence-driven solutions, and detection systems through its subsidiaries and strategic collaborations. The company collaborates with technology partners to distribute and promote new systems such as 3D imaging and electromagnetic threat detection tools, autonomous security technologies, and multi-layered security ecosystems for critical infrastructure and high-traffic venues.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.